Amarin Corp Plc (AMRN)

[HDGabor]

c-

Is Singer challenging this in brief?

Nope, he is challenging the LDL-C part. (please note: my point was about TG lowering effect only)

If I remember correctly, you think he did a great job here, right?

Yes. I did not expect the HTG vs VHTG argument

HTG vs VHTG (different MOA)

Amarin tried to convince the USPTO and the DC about it … without any success. As it is a factual finding, the CAFC could (and most likely will) defer to the DC (and to the USPTO) if Amarin will raise it (I do not expect.).

but I see his approach as brilliant. Meanwhile he details the factual error, he made it as a procedural error, as generics have to prove that the MOA is the same (vs. Amarin has to prove it is different).

IIRC generics did not details, provide any evidence for same MOA (IIRC Markmans mentioned it also in one post).

Best,
G